A real-world dataset reported that Nefecon—targeted-release budesonide—reduced proteinuria and helped preserve kidney function in primary IgA nephropathy, including patients starting at relatively low baseline proteinuria levels. The findings support the use of targeted corticosteroid delivery strategies beyond trial populations and into routine care. For nephrology practice, the update centers on durability of renal protection and the ability to extend response to broader patient subgroups. It also reinforces the shift toward localized immunomodulation to limit systemic steroid exposure.